Table of Content - Human Recombinant Insulin Market

Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilars analogue of insulin, worldwide.

Market Dynamics

Sedentary and unhealthy lifestyle, unhealthy eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. For instance, on November 16, 2021, Viatris Inc., a pharmaceutical company and Biocon Biologics Ltd., a biopharmaceutical company announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilars products are available in vial and prefilled pen.

Key features of the study:

This report provides an in-depth analysis of the global human recombinant insulin market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human recombinant insulin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human recombinant insulin market

Detailed Segmentation:

Global Human Recombinant Insulin Market, By Product Type:
- Rapid-Acting Human Insulin
- Short-Acting Human Insulin
- Intermediate-Acting Human Insulin
- Long-Acting Human Insulin
- Premixed Human Insulin
Global Human Recombinant Insulin Market, By Brand:
- Humalog
- Novolog
- Apidra
- Humulin R
- Novolin R
- Humulin N
- Novolin N
- Levemir
- Lantus
- Humalog Mix
- Novolog Mix
- Others
Global Human Recombinant Insulin Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Human Recombinant Insulin Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Novo Nordisk A/S *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Eli Lilly and Company
- Sanofi S.A.
- Julphar Gulf Pharmaceutical Industries
- Biocon Limited
- Bioton S.A.
- Gan & Lee Pharmaceuticals, Ltd.
- Zhuhai United Laboratories Co., Ltd.
- Wanbang Biopharmaceuticals Co., Ltd.
- Dongbao Enterprise Group Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Product Type
  - Market Snapshot, By Brand
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Key Highlights
- Market Trends
- PEST Analysis
- Government & Non-Government Initiatives
- Epidemiology
Global Human Recombinant Insulin Market – Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
Global Human Recombinant Insulin Market, By Product Type, 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Rapid-Acting Human Insulin
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Short-Acting Human Insulin
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Intermediate-Acting Human Insulin
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Long-Acting Human Insulin
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Premixed Human Insulin
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Global Human Recombinant Insulin Market, By Brand , 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Humalog
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Novolog
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Apidra
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Humulin R
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Novolin R
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Humulin N
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Novolin N
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Levemir
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Lantus
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Humalog Mix
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Novolog Mix
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million
Global Human Recombinant Insulin Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- - Introduction
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 20230
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Million)
Global Human Recombinant Insulin Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
  - Market Share Analysis, By Region, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, For Regions, 2017–2030
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Brand , 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Brand , 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Brand , 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - UK
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Brand , 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Brand , 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Brand , 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profiles
  - Novo Nordisk A/S
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Eli Lilly and Company
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Sanofi S.A.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Julphar Gulf Pharmaceutical Industries
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Biocon Limited
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Bioton S.A.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Gan & Lee Pharmaceuticals, Ltd.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Zhuhai United Laboratories Co., Ltd.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Wanbang Biopharmaceuticals Co., Ltd.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Dongbao Enterprise Group Co., Ltd.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
Section
- Research Methodology
- About Us

*Browse 34 market data tables and 38 figures on "Global Human Recombinant Insulin Market” - forecast to 2030

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount